Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-ROR1-2-L1
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-NOTA-ROR1-2-L1 is a novel peptide-based positron emission tomography (PET) radiotracer designed for the non-invasive, quantitative assessment of receptor tyrosine kinase-like orphan receptor 1 (ROR1) expression. Developed by researchers at Huazhong University of Science and Technology and Zhejiang University, the tracer consists of a ROR1-targeting peptide (ROR1-2-L1) conjugated to the chelator NOTA and labeled with the positron-emitting radionuclide gallium-68 (68Ga). ROR1 is highly expressed in various malignancies, including melanoma, chronic lymphocytic leukemia, lung adenocarcinoma, and breast cancer, while being nearly absent in normal adult tissues. In preclinical melanoma models, 68Ga-NOTA-ROR1-2-L1 demonstrated high radiochemical purity, rapid tumor accumulation, and excellent tumor-to-muscle contrast, making it a promising diagnostic tool for patient stratification and monitoring therapeutic efficacy in ROR1-targeted therapies.
- Other names
- [68Ga]Ga-NOTA-ROR1-2-L1⁶⁸Ga-NOTA-ROR1-2-L1
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)
Beyond the preview
Go deeper on 68Ga-NOTA-ROR1-2-L1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-ROR1-2-L1.